Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

  • Technology appraisal guidance
  • TA317
  • Published: 
Download guidance (PDF)

1 Recommendations

This guidance replaces NICE's technology appraisal guidance 182 on prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention.

1.1

Prasugrel 10 mg in combination with aspirin is recommended as an option within its marketing authorisation, that is, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina [UA], non-ST segment elevation myocardial infarction [NSTEMI] or ST segment elevation myocardial infarction [STEMI]) having primary or delayed percutaneous coronary intervention.